; (3) in subsection (f)(1), by striking $610,000,000 for each of fiscal years 2019 through 2021, and $750,000,000 for each of fiscal years 2022 and 2023 and inserting $965,000,000 for each of fiscal years 2024 through 2028 ; and (4) in subsection (g)(1), by striking 2019 through 2028 and inserting 2024 through 2033 . 207. Medical countermeasures for viral threats with pandemic potential Section 319L of the Public Health Service Act ( 42 U.S.C. 247d–7e ) is amended— (1) in subsection (c)(4)— (A) in subparagraph (D), by amending clause (iii) to read as follows: (iii) conduct research to promote strategic initiatives, such as— (I) rapid diagnostics; (II) broad spectrum antimicrobials; (III) medical countermeasures for virus families that have significant potential to cause a pandemic, including such countermeasures that take either pathogen-specific or broad spectrum approaches; and (IV) technologies to improve the production and use of medical countermeasures, which may include vaccine-manufacturing technologies, dose-sparing technologies, efficacy-increasing technologies, platform technologies, technologies to administer countermeasures, and technologies to improve storage and transportation of countermeasures. ; and (B) in subparagraph (F), by amending clause (ii) to read as follows: (ii) threats that— (I) (aa) consistently exist or continually circulate and have a significant potential to become a pandemic, such as pandemic influenza; or (bb) include priority virus families and other viral pathogens with a significant potential to cause a pandemic; and (II) may include the advanced research and development, manufacturing, and appropriate stockpiling of qualified pandemic or epidemic products, and products, technologies, or processes to support the advanced research and development of such countermeasures (including multiuse platform technologies for diagnostics, vaccines, and therapeutics; virus seeds; clinical trial lots; novel virus strains; and antigen and adjuvant material);